
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2024; Massachusetts Medical Society; Volume: 391; Issue: 5 Linguagem: Inglês
10.1056/nejmoa2405090
ISSN1533-4406
AutoresVânia Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, Ana Carolina Ribas de Almeida, Roman Hájek, Kihyun Kım, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Martínez, Anna Maria Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios Α. Dimopoulos, Chengcheng Fu, Mamta Garg, Al‐Ola Abdallah, Albert Oriol, Moshe E. Gatt, Michèle Cavo, Robert M. Rifkin, Tomoaki Fujisaki, Michał Mielnik, Nick Pirooz, Astrid McKeown, Simon McNamara, Xiangdong Zhou, Maureen Nichols, Eric Lewis, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opalińska, María-Victoria Mateos,
Tópico(s)Peptidase Inhibition and Analysis
ResumoBelantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies.
Referência(s)